Theralase Technologies Inc. announced that its Phase II clinical study (Study II) interim data was recently presented at the American Society of Clinical Oncology (ASCO) Genito Urinary (GU) Cancer Symposium via a moderated poster presentation. Study II has been designed to treat patients diagnosed with Bacillus Calmette-Guérin (BCG)-Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ (CIS) (with or without resected papillary Ta/T1 disease) with a patented investigational study drug (TLD-1433) (Trade Name: Ruvidar), a ruthenium based PDC intravesically instilled into a patient's bladder, then subsequently activated by a proprietary investigational study device (TLC-3200), a green (520 nm) laser system equipped with fiber-optic light emitters and detectors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.14 CAD | -3.45% | -12.50% | -20.00% |
04-24 | Theralase Technologies Inc. announced that it has received CAD 0.7502 million in funding | CI |
04-05 | Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.00% | 24.55M | |
-28.52% | 225M | |
-31.21% | 79.33M | |
+26.41% | 68.5M |
- Stock Market
- Equities
- TLT Stock
- News Theralase Technologies Inc.
- Theralase Technologies Inc. Announces Phase II NMIBC Clinical Study Data Presented at the ASCO GU Cancer Symposium